Tolera Therapeutics Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Tolera Therapeutics General Information
Description
Developer of immune modulation transplant therapies created to address unmet medical needs with safer, targeted solutions. The company's immune modulation transplant therapies target the human alpha-beta T-cell receptor that appears to render pathologic T-cells inert and through a unique signaling pathway that expands regulatory T-cells in a novel, non-depleting manner, enabling the lives of patients suffering from a broad spectrum of autoimmune and immune-meditated diseases to improve.
Contact Information
Website
www.tolera.comCorporate Office
- P.O. Box 970
- Portage, MI 49081
- United States
Corporate Office
- P.O. Box 970
- Portage, MI 49081
- United States
Tolera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 01-Feb-2017 | Completed | Out of Business | |||
| 7. Later Stage VC | 17-Sep-2014 | Completed | Generating Revenue | |||
| 6. Angel (individual) | 13-Sep-2013 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B3) | 16-Oct-2012 | Completed | Generating Revenue | |||
| 4. Angel (individual) | 01-Dec-2011 | Completed | Startup | |||
| 3. Early Stage VC (Series B) | 07-Jun-2010 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 16-Jun-2008 | $7.84M | $7.84M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Tolera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B1 | 17,313,277 | $0.001000 | $0.06 | $0.72 | $0.72 | 1x | $0.72 | 40.41% |
| Series A | 11,872,094 | $0.001000 | $0.05 | $0.66 | $0.66 | 1x | $0.66 | 27.71% |
Tolera Therapeutics Patents
Tolera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2012332193-A1 | Antibody and methods for selective inhibition of t-cell responses | Inactive | 03-Nov-2011 | ||
| CA-2853687-A1 | Antibody and methods for selective inhibition of t-cell responses | Inactive | 03-Nov-2011 | ||
| EP-2773670-A2 | Antibody and methods for selective inhibition of t-cell responses | Inactive | 03-Nov-2011 | ||
| EP-2773670-A4 | Antibody and methods for selective inhibition of t-cell responses | Inactive | 03-Nov-2011 | ||
| WO-2013067517-A2 | Antibody and methods for selective inhibition of t-cell responses | Inactive | 03-Nov-2011 | C07K16/2803 |
Tolera Therapeutics FAQs
-
When was Tolera Therapeutics founded?
Tolera Therapeutics was founded in 2007.
-
Where is Tolera Therapeutics headquartered?
Tolera Therapeutics is headquartered in Portage, MI.
-
What industry is Tolera Therapeutics in?
Tolera Therapeutics’s primary industry is Pharmaceuticals.
-
Is Tolera Therapeutics a private or public company?
Tolera Therapeutics is a Private company.
-
What is Tolera Therapeutics’s current revenue?
The current revenue for Tolera Therapeutics is .
-
How much funding has Tolera Therapeutics raised over time?
Tolera Therapeutics has raised $19.4M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process